We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Automated Glycated Hemoglobin Assay Now Certified by US Glycohemoglobin Standardization Program

By LabMedica International staff writers
Posted on 24 Jul 2014
Print article
Image: The CLC720 chemistry analyzer (Photo courtesy of the Carolina Liquid Chemistries Corporation).
Image: The CLC720 chemistry analyzer (Photo courtesy of the Carolina Liquid Chemistries Corporation).
An assay for the measurement of glycated hemoglobin (HbA1c) designed for use on a new-generation automated chemistry analyzer was recently certified by the [US] National Glycohemoglobin Standardization Program (NGSP).

HbA1c is a derivative of hemoglobin that is formed nonenzymically by reaction at the N terminus of the protein molecule with glucose. In the normal adult human such derivatives constitute a few percent of the total erythrocyte hemoglobin, the most abundant being hemoglobin A1c, which increases several fold in concentration in diabetes mellitus, and is assayed to monitor control of diabetes. Once a hemoglobin molecule is glycated, it remains that way. A buildup of glycated hemoglobin within the red cell, therefore, reflects the average level of glucose to which the cell has been exposed during its life-cycle. Measuring glycated hemoglobin assesses the effectiveness of therapy by monitoring long-term serum glucose regulation. The HbA1c level is proportional to average blood glucose concentration over the previous four weeks to three months.

In the United States, HbA1c testing laboratories are certified by the National Glycohemoglobin Standardization Program (NGSP) to standardize them against the results of the 1993 Diabetes Control and Complications Trial (DCCT). This landmark study showed that the risk for development and progression of the chronic complications of diabetes was closely related to the degree of glycemic control, as measured by HbA1c. The DCCT also provided a large body of data relating HbA1c values to mean blood glucose.

Carolina Liquid Chemistries Corporation (Winston-Salem, NC, USA) recently announced today that its new Hemoglobin A1c test (HbA1c-direct), designed for use on the CLC720 chemistry analyzer had been certified by the NGSP.

“There are other HbA1c tests on the market,” said Patricia Shugart, chief operating officer at Carolina Liquid Chemistries Corporation, “but our HbA1c-direct is special in two ways. First, it’s a direct test, meaning there is no manual sample pretreatment. Second, it is categorized as moderately complex, which avoids the extra cost of a high complexity lab.”

The speed and ease of HbA1c-direct is made possible by the enhanced capabilities of the CLC720 chemistry analyzer, which, unlike most analyzers in its class, automates the lysing step that would otherwise have to be performed manually.

“Our test correlates to the NGSP certified tests used in large-scale diabetes studies,” said Patricia Shugart. “Physicians can now relate their HbA1c-direct results to these studies, providing more relevance.”

Related Links:
Carolina Liquid Chemistries Corporation



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more